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analogue drug hits in wild-type embryos. Of these drugs, 
9/14 and 7/14, respectively, are known to target pathways 
implicated in osteoarthritis pathogenesis or to cause re-
duced bone mineral density/increased fracture risk as side 
effects in patients treated for other conditions, suggesting 
that our screen enriched for pathways targeting skeletal tis-
sue homeostasis. We selected one drug that inhibited NCSC 
induction and one drug that inhibits bone mineralisation for 
further detailed analyses which reflect our initial hypothe-
ses. These drugs were leflunomide and cyclosporin A, re-
spectively, and their functional analogues, teriflunomide 
and FK506 (tacrolimus). We identified their critical develop-
mental windows of activity, showing that the severity of de-
fects observed related to the timing, duration, and dose of 
treatment. While leflunomide has previously been shown to 
inhibit NCSC induction, we demonstrate additional later 
roles in cartilage remodelling. Both drugs altered expression 
of extracellular matrix metalloproteinases. As proof-of-con-
cept, we also tested drug treatment of disease-relevant 
mammalian cells. While leflunomide treatment inhibited the 
viability of several human NCSC-derived neuroblastoma cell 
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 Abstract 
 Neural crest stem/progenitor cells (NCSCs) populate a vari-
ety of tissues, and their dysregulation is implicated in sev-
eral human diseases including craniosynostosis and neu-
roblastoma. We hypothesised that small molecules that 
inhibit NCSC induction or differentiation may represent po-
tential therapeutically relevant drugs in these disorders. We 
screened 640 FDA-approved compounds currently in clinical 
use for other conditions to identify those which disrupt de-
velopment of NCSC-derived skeletal elements that form the 
zebrafish jaw. In the primary screen, we used heterozygous 
transgenic  sox10:gfp  zebrafish to directly visualise NCSC-de-
rived jaw cartilage. We noted partial toxicity of this trans-
gene in relation to jaw patterning, suggesting that our pri-
mary screen was sensitised for NCSC defects, and we con-
firmed 10 novel, 4 previously reported, and 2 functional 
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lines coincident with altered expression of genes involved in 
ribosome biogenesis and transcription, FK506 enhanced 
murine calvarial osteoblast differentiation and prevented fu-
sion of the coronal suture in calvarial explants taken from 
Crouzon syndrome mice.  © 2018 The Author(s) 
Published by S. Karger AG, Basel 
 Craniosynostosis, premature fusion of sutures within 
the skull at birth, is a relatively common and serious con-
dition affecting approximately 1 in 2,100 children [Hehr 
and Muenke, 1999; Wilkie et al., 2010]. A major focus of 
research into craniosynostosis is to identify drug treat-
ments to improve outcomes following corrective surgery 
for this condition. The calvarium (or skull vault) forms 
through the process of intramembranous ossification 
[Twigg and Wilkie, 2015]. The cranial sutures are the ma-
jor site of new bone formation within the skull, where 
osteoblasts form bone directly within the mesenchyme 
without the need for a cartilage anlagen. In simple terms, 
the formation of new bone and maintenance of suture 
patency is driven by the balance between osteoblast pro-
liferation and differentiation. As such, osteoblasts have 
long been considered an obvious target for chemical ther-
apies for craniosynostosis. However, cultured chick and 
rodent calvarial mesenchyme expresses chondrocyte-
specific collagen isoforms and can differentiate into both 
osteoblasts and chondrocytes, and small islands of carti-
lage can form within the cranial sutures [Aberg et al., 
2005]. Therefore, calvarial mesenchyme has been pro-
posed to have dual osteoblast and chondrogenic identity. 
The finding of mutations in interleukin genes in syn-
dromes featuring immunodeficiency, failed molar tooth 
eruption, and craniosynostosis also suggests the involve-
ment of bone-resorbing osteoclasts in maintenance of su-
ture patency [Nieminen et al., 2011; Keupp et al., 2013; 
Schwerd et al., 2017]. Therefore, several key bone cell 
types are potentially relevant targets for treatment of cra-
niosynostosis.
 Neural crest stem/progenitor cells (NCSCs) are a tran-
sient population of embryonic multipotent stem cells that 
are induced at the lateral margins of the neural plate and 
migrate extensively to populate a variety of tissues. Sev-
eral lines of evidence suggest that NCSC patterning de-
fects cause craniosynostosis. Within the skull, NCSCs 
have been shown to make a significant contribution to the 
frontal bones of the skull and the sagittal suture, but they 
make no contribution whatsoever to the parietal bone or 
coronal suture [Jiang et al., 2002].  Twist  mutant mice ex-
hibit coronal craniosynostosis with mislocalisation of 
NCSCs within the coronal sutures and parietal bone 
[Merrill et al., 2006]. Knockout of the  Msx2  gene, which 
drives osteoblast differentiation within the skull, rescued 
these defects, leading to proposal of a model whereby ec-
topic localisation of NCSCs to the coronal suture and pa-
rietal bone leads to enhanced osteoblast differentiation. 
Ephrin signalling is known to regulate NCSC migration, 
and thus heterozygosity for  EFNB1  mutations in cranio-
frontonasal syndrome have been suggested to cause cra-
niosynostosis secondary to cellular interference and 
NCSC migration defects in female foetuses (it should be 
noted, however, that EFNB1 has also been shown to regu-
late osteoblast differentiation directly) [Twigg et al., 2004, 
2006, 2013; Babbs et al., 2011; Cheng et al., 2013]. En-
grailed 1 ( En1 ) has also been identified as a necessary reg-
ulator of cell movement and neural crest/mesoderm lin-
eage boundary positioning during coronal suture forma-
tion [Deckelbaum et al., 2012]. Given these findings, we 
hypothesised that drugs which inhibit NCSC identities or 
their subsequent differentiation/remodelling could be 
therapeutically relevant in craniosynostosis.
 The zebrafish has emerged as a powerful model organ-
ism for in vivo drug screening [Wiley et al., 2017]. As a 
vertebrate model, it presents several key advantages in-
cluding large clutch size and fecundity, external embry-
onic development, visual transparency, and genetic trac-
tability (although recent results from reverse genetics 
suggest that the zebrafish has become redundant as a ge-
netic model owing to compensatory mechanisms and 
gene redundancy). Oxygen also diffuses freely into ze-
brafish embryos, which is a key advantage, allowing em-
bryos to survive drug treatments that can frequently dis-
rupt cardiovascular system formation. While zebrafish 
embryos develop rapidly, their subsequent growth and 
maturation is relatively much slower. In particular, the 
membranous bones of the skull vault do not ossify over 
the brain until the second month of life, thereby preclud-
ing drug screens based on calvarial development in this 
organism [Mork and Crump, 2015].
 An important consideration relates to drug screen de-
sign, which generally falls into 1 of 2 camps. One option 
is a “modifier” screen, whereby a faithful (typically ge-
netic) model of disease is treated with drugs in an attempt 
to ameliorate a disease phenotype. A second option that 
we will refer to as a “perturbation” screen involves the 
testing of drugs for their ability to generate a phenotype 
in otherwise wild-type/normal animals. This approach 
requires careful selection of a cell type that is relevant to 
a disease and analysis of a specific marker of these cells in 
order to identify drugs that are therapeutic. Perturbation 





screens can also allow investigation of drug teratogenic-
ity. For example, many drugs are known to disrupt cra-
niofacial/skeletal development and tissue homeostasis as 
side effects, e.g., association between valproate ingestion 
during pregnancy and craniosynostosis [Twigg and Wilk-
ie, 2015]. Clearly, perturbation screens would require 
subsequent validation/follow-up in a (mammalian) dis-
ease-relevant model. Given that perturbation screens are 
disruptive in their design, they have the advantage of be-
ing less sensitive to genetic threshold effects and buffering 
mechanisms within a network than modifier screens, and 
may therefore be more transferrable across species.
 While perturbation screens may seem counterintui-
tive in terms of therapy, this approach has proved to be 
highly productive, whereas the published evidence has 
demonstrated the modifier approach to be far less suc-
cessful. Approximately 30 unbiased in vivo  drug screens 
using zebrafish have been reported to date to our knowl-
edge, and all but 4 of these were based on the perturbation 
design [Peterson et al., 2004; Stern et al., 2005; North et 
al., 2007; Kitambi et al., 2009; Ishizaki et al., 2010; Paik et 
al., 2010; Rihel et al., 2010; Ni et al., 2011; Peal et al., 2011; 
Rovira et al., 2011; Namdaran et al., 2012; Ridges et al., 
2012; Gut et al., 2013; Le et al., 2013; Kong et al., 2014; 
Mork and Crump, 2015]. This suggests a reporting bias 
such that most of the many modifier screens that we know 
to have been conducted in the field have not yielded any 
hits. Of 4 published modifier screens, an average con-
firmed drug hit rate of 0.086% (range 0.17–0.06%) was 
reported [Peterson et al., 2004; Stern et al., 2005; Paik et 
al., 2010; Peal et al., 2011], whereas for perturbation 
screens that reported their results in full, an average con-
firmed hit rate of 2.50% (range 8.2–0.08%) was achieved 
[North et al., 2007; Kitambi et al., 2009; Ishizaki et al., 
2010; Rihel et al., 2010; Ni et al., 2011; Rovira et al., 2011; 
Namdaran et al., 2012; Ridges et al., 2012; Gut et al., 2013; 
Le et al., 2013; Kong et al., 2014; Mork and Crump, 2015]. 
Thus a typical screen of 1,000 small molecules, which is 
achievable in most labs using nonautomated zebrafish 
screens, is expected to produce 25 hits in a perturbation 
screen but none in a modifier screen. Clearly, there is also 
likely to be a significant rate of attrition in transferring 
suitable drug hits to mammalian systems for treatment of 
disease, and so a number of hits are likely to be required 
for a realistic chance of translation.
 The zebrafish viscerocranium is derived from NCSCs 
that contribute to the 7 pharyngeal arch derivatives, in-
cluding the mandible/Meckel cartilages and the ptery-
goid/ethmoid plate complex, which constitute the most 
anterior aspects of the lower and upper jaw, respectively 
[Schilling and Kimmel, 1997; Mork and Crump, 2015]. 
The lower jaw consists of 7 paired and bilaterally sym-
metric cartilage elements. In anteroposterior sequence, 
these include Meckel cartilage, the ceratohyoid cartilage 
and arches 3–7 which consist of ceratobranchials at-
tached to hypobranchials. These elements are arranged in 
a stereotypical pattern and are composed of chondrocytes 
that first emerge during the third day post-fertilisation 
(dpf). These cells are derived from cranial NCSCs that are 
first induced in the neural plate border at the earliest so-
mite stages and subsequently migrate through the bran-
chial arches. Failed NCSC induction prevents formation 
of this cartilage, and many zebrafish models of abnormal 
patterning/migration of NCSCs have been shown to ex-
hibit quantitative increases in the angle between the 
paired cartilage elements and particularly the ceratohyoid 
cartilages. Once formed, these cartilage elements are re-
modelled through convergent extension cell movements 
of chondrocytes, enzymatic regulation of extracellular 
matrix glycosaminoglycans, and cellular hypertrophy. 
Both osteoblasts and osteoclasts localise throughout the 
zebrafish jaw at these stages or shortly afterwards [Eames 
et al., 2013; Sharif et al., 2014; Mork and Crump, 2015]. 
Anatomically, this manifests as a progressive reduction in 
the angle between the ceratohyoids and the other bran-
chial arch cartilages between 3–5 dpf.
 Here, we report a drug screen of FDA-approved com-
pounds that disrupt ceratohyoid cartilage formation in a 
perturbation screen. We report a hit rate consistent with 
published perturbation screens, and we enrich for novel 
“hits” that target skeletal tissue homeostasis. Our results 
demonstrate the importance of sustained drug treatment, 
which might be necessary to overcome compensatory 
mechanisms and could have relevance in future clinical 
translation. As proof-of-concept, we demonstrate possi-
ble efficacy of 2 compounds in mammalian ex vivo mod-
els of disease, including treatment of craniosynostosis.
 Materials and Methods 
 Zebrafish 
 Zebrafish ( Danio rerio ) embryos were obtained from a wild-
type strain and raised at 28.5 ° C in accordance with Home Office 
licence PPL 70/7892. Heterozygous  sox10:gfp zebrafish were 
crossed to wild types to produce heterozygous embryos. Embryos 
were cultured in 24-well plates (3 per well) and treated with one of 
640 FDA-approved drugs from the Enzo BML-2842 (v1.5) library, 
from mid- to late-gastrulation (8 hours post-fertilisation; hpf) un-
til 5 dpf, at which stage NCC-derived craniofacial cartilage was 
imaged. Drugs stocks were stored at –80   °   C at 10 m M in DMSO. 
For drug treatments, small molecules were defrosted at 37   °   C and 





diluted to 10 μ M in E3 medium. In the secondary screen, putative 
drug hits were re-tested on >10  sox10:gfp  heterozygotes, and in the 
tertiary screen, hits were tested on wild-type zebrafish stained us-
ing Alcian blue. In situ hybridisation was performed by standard 
techniques, using RNA probes labelled with digoxigenin (Roche) 
and detected using NBT/BCIP (Sigma). We note that, in order to 
aid visualisation of cartilage elements in Figure 4 only, PTU treat-
ment was used in this particular experiment. However, throughout 
our drug screen and in subsequent analyses, PTU was not used, as 
this has been shown to sensitise zebrafish to jaw patterning defects 
through dysregulated retinoic acid signalling. Findings in this ex-
periment were confirmed in parallel in embryos not treated with 
PTU.
 Neuroblastoma Cell Culture 
 Neuroblastoma cell lines SK-N-AS, SK-N-SH, IMR32, and 
LAN5 are derived from the neural crest lineage within the adrenal 
gland. Cells were cultured in RPMI medium and 10% fetal calf se-
rum, except for SK-N-SH which used MEME medium plus 10% 
fetal calf serum. Cells have been STR genotyped by ATCC or by 
the group of Frank Speleman, University of Ghent. For cell prolif-
eration assays with leflunomide or teriflunomide, between 10,000 
and 20,000 cells were plated per well in 96-well plates, and these 
were grown in the presence or absence of chemicals for 3 days, be-
fore being processed with Cell Cycle Kit-8 as per manufacturer’s 
protocol (Sigma Aldrich). Absorbance values were measured at 
OD450nm and background (no cells) values subtracted before 
normalisation against untreated samples.
 RNAseq and Analysis 
 The stranded total RNA libraries were prepared in accordance 
to the Illumina TruSeq Stranded mRNA Sample Preparation (Oc-
tober 2013 Rev E.) for Illumina Paired-End Multiplexed Sequenc-
ing. Poly-A mRNA in the tRNA samples were first purified using 
Illumina poly-T oligo-attached magnetic beads and 2 rounds of 
purification. During the second elution of the poly-A RNA, the 
mRNA were also fragmented and primed with random hexamers 
for cDNA synthesis. Cleaved RNA fragments that were primed 
with random hexamers were reverse transcribed into first strand 
cDNA using reverse transcriptase and random primers followed 
by second strand cDNA synthesis. A single “A” nucleotide is add-
ed to the 3 ′ end of the blunt fragments to prevent ligating to one 
another during adapter ligation reaction. The adapters and index-
es are ligated to the end of the double-stranded cDNA to prepare 
the sample for hybridisation onto a flow cell. The sample is then 
PCR amplified through 15 cycles of PCR to select samples that 
have the adapter molecules present on both ends of the DNA. The 
libraries were validated on the Agilent BioAnalyser 2100 to check 
the size distribution of the libraries and on the Qubit High Sensi-
tivity to check the concentration of the samples. The pool was then 
loaded at a concentration of 8 p M onto 1 lane of an Illumina 
HiSeq2000 flow cell v3. Samples were sequenced using 100 bp SE 
runs. KEGG pathway gene ontology terms statistically significant-
ly enriched within the list of differentially expressed genes (log 2 -
fold change >2;  p < 0.05) while identified according to DAVID 
software analysis (https://david.ncifcrf.gov/).
 Calvarial Explant Culture 
 We tested FK506 for rescue of craniosynostosis in a calvarial 
explant system that we and others have developed using Crouzon 
mice [Eswarakumar et al., 2006]. Heterozygous stud males carry-
ing the  Fgfr2 C342Y mutation were crossed with wild-type females on 
a CD-1 genetic background. Typically 8–12 pups were produced, 
with an expected 50: 50 ratio of heterozygotes and wild types. Pups 
were sacrificed at embryonic day (E) 18.5. Skin was removed from 
the scalp, the skull base was dissected and this and the brain were 
discarded. No attempt to remove dura or other tissue was made. 
Explants were cultured in one well of a 12-well plate in 2 mL of 
DMEM F12 medium (Gibco) supplemented with 10% fetal bovine 
serum. Explants were cultured for 14 days. Media was changed ev-
ery 2 days and included 100 n M FK506 dissolved in DMSO, or 
DMSO alone, as a control. Differentiation of primary osteoblasts 
derived from wild-type CD-1 calvarial from 4-day-old mice and 
grown for 14 days.
 Primary Osteoblast Culture 
 Primary mouse osteoblastic cells were obtained by sequential 
enzyme digestion of excised calvarial bones from 4-day-old CD1 
mice using a 3-step process (1% trypsin in PBS for 10 min, 0.2% 
collagenase type II in Hanks balanced salt solution (HBSS) for 30 
min, and 0.2% collagenase type II in HBSS for 60 min). The first 2 





Drug – Enzo library
(640 compounds – 
10 μM in 500 μL E3 
medium)
 Fig. 1. Overview of zebrafish drug screen employed in this study. 
Three embryos from a wild-type x  sox10:gfp  heterozygote cross  per 
well were treated with one of 640 FDA-approved drugs in a 24-well 
plate format from 8 hours post-fertilisation (hpf) and screened for 
quantitative increases in the angle of the ceratohyoid cartilage or 
gross malformations at 5 days post-fertilisation (dpf). 





mented with 10% FCS, 2 m M L-glutamine, 1% gentamicin, 100 U/
mL penicillin, 100 μg/mL streptomycin and 0.25 μg/mL ampho-
tericin. Cells were cultured for 2–4 days at 37   °   C in 5% CO 2 until 
they reached confluence. They were then cultured in 6-well trays 
in MEM supplemented with 2 m M β-glycerophosphate and 50 μg/
mL ascorbic acid, with half medium changes every 3 days. FK506 
(0, 0.001, 0.01, 0.1, 1, and 10 n M ) was added to the culture every 3 
days from day after seeding. Total RNA were extracted from cells 
at day 14 (differentiating osteoblasts) using TRIzol ® reagent 
(Thermo Fisher) according to manufacturer’s instructions.
 cDNA was reverse-transcribed from 1 μg of total RNA using 
Omniscript RT kit (Qiagen). Real-time qPCR was carried out us-
ing iTaq TM Universal SYBR Green supermix (Bio-Rad) with prim-
ers for the mouse Hprt (forward, GCAGTACAGCCCCAAAATGG; 
reverse, AACAAAGTCTGGCCTGTATCCAA),  Col1A1 (for-
ward, GGTCCTCGTGGTGCTGCT; reverse, ACCTTTGCCC-
CCTTCTTTG),  Alp (forward, GATAACGAGATGCCACCAG-
AGG; reverse, TCCACGTCGGTTCTGTTCTTC),  Osx (forward, 
ATGGCGTCCTCTCTGCTTG; reverse, TGAAAGGTCAGCGT-
ATGGCTT), and  Runx2 (forward, GACTGTGGTTACCGTC-
ATGGC; reverse, ACTTGGTTTTTCATAACAGCGGA) genes.
 Results 
 A Sensitised Screen for FDA-Approved Drugs 
Targeting Craniofacial Neural Crest 
 Given that abnormal location of NCSCs within the 
coronal suture or parietal bone has been proposed to 
drive ectopic osteoblast differentiation and cranial suture 
fusion, we hypothesised that small molecules that inhibit 
NCSC induction or their subsequent differentiation 
could be therapeutically relevant in craniosynostosis. Fol-
lowing the rationale outlined above, we designed a per-
turbation screen using  sox10:gfp  transgenic zebrafish in 
which green fluorescent protein (GFP) expression is driv-
en by 4.9 kb of the zebrafish  sox10  promoter/upstream 
sequence [Dutton et al., 2008]. In this line, neural crest-
derived craniofacial cartilage making up the jaw is la-
belled with GFP, allowing direct visualisation of these 
structures in live embryos ( Fig. 1 ). During the course of 
our initial studies, we noticed that one quarter of fry from 
an incross of  sox10:gfp  heterozygotes demonstrated se-
vere abnormalities of the jaw, including a strong reduc-
tion in Meckel cartilage and severe widening of the cera-
tohyoids and ceratobranchials ( Fig.  2 A–C), suggesting 
that the transgene is toxic to NCSC patterning when ho-
mozygous. We therefore included only heterozygous 
transgenic zebrafish in our screen by crossing heterozy-
gous females with wild-type males. We included 3 fish per 
well in a 24-well plate format. On average, 50% of fry were 
heterozygous and could therefore be analysed in our 
screen.
 In the primary screen, the effects of 640 FDA-approved 
drugs were tested by treating embryos from 8 hpf [equat-
ing to approximately 50% epiboly (E50)] to avoid defects 































Embryos 1–152 Embryos 1–871
sox10:gfp




Av. 60.11° (95% CI: 37.22–83.00)
sox10:gfp (het, GFP)
Av. 92.17° (95% CI: 55.24–129.10)
D
A B C
 Fig. 2.  sox10:gfp  transgenic embryos are 
sensitised for jaw patterning defects.  A–
C Ventral views of wild-type zebrafish ( A ) 
or fry that are heterozygous ( B ) or homo-
zygous ( C ) for the  sox10:gfp  transgene. 
Note the gross structural abnormalities in 
homozygotes.  D Angles between the cera-
tohyoid cartilages for each of the 152 wild-
type zebrafish (left) and 871 heterozygous 
transgenics (right)  at 5 days post-fertiliza-
tion. Av, average; CI, confidence interval; 
GFP, green fluorescent protein; hom, ho-
mozygous; het, heterozygous. 





ery embryo was manually photographed ( Fig. 1 ). Embry-
os were treated with a standard 10 μ M dose of each of 640 
compounds from the Screen-Well ® FDA-approved drug 
library (Enzo, BML-2842 version 1.5) in E3 medium. This 
is a dose at which most bioactive compounds have been 
shown to be effective [Rennekamp and Peterson, 2015]. 
Measurement of the ceratohyoid jaw angle in the 871 het-
erozygous transgenic animals that were included in our 
primary screen revealed an average angle of 92.17°, 
whereas wild-type embryos stained for Alcian blue had an 
average angle of 60.11° ( Fig. 2 D). Not a single transgenic 
animal exhibited an angle as low as the average value for 
wild types. This suggests that the  sox10:gfp  transgene is 
therefore partially toxic in heterozygotes, and that our 
screen was sensitised for NCSC patterning defects.
 In the primary screen, we identified 3 categories of 
candidate hits ( Fig. 3 A). This included drugs that were 
associated with: (i) a quantitatively increased angle be-
tween the ceratohyoid cartilages as a purely objective 
measure, (ii) gross morphological defects, or (iii) no GFP 
expression. Given the breeding scheme used, the latter 
would be expected in 12.5% of embryo trios by chance 
alone. In total, 156 putative hits were identified in the pri-
mary screen, including 30, 88, and 38 of categories i, ii, 
and iii, respectively ( Fig. 3 B). In a secondary screen, these 
compounds were each re-tested on approximately 10 
transgenic animals, and reproducible hits here were test-
ed in a tertiary screen for their effects on wild-type zebraf-
ish that were stained for Alcian blue. Of the 640 com-
pounds screened, 14 (2.2%) had reproducible effects on 
craniofacial cartilage in all 3 screens ( Fig. 3 ,  4 , and data 
not shown). We also re-ordered each of the 14 drugs that 
caused consistent phenotypes across all 3 screens from 
independent sources and tested them to exclude artefacts 
relating to chemical batch. Ten of these compounds were 
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 Fig. 3. Drug screen results.  A Examples of 
morphological phenotype categories iden-
tified in the screen, in comparison to nor-
mal control zebrafish.  B Summary statistics 
of the number of drugs represented by each 
category in each of the 4 stages of screen-
ing/re-testing. 





craniofacial development to our knowledge. Four of the 
hits we describe (pimozide, retinoic acid, nisoldipine, and 
leflunomide) were previously reported in a recent screen 
of zebrafish craniofacial development with a similar de-
sign to ours [Kong et al., 2014]. Notably, of the 38 drugs 
associated with no GFP expression in the primary screen, 
only 1 drug (leflunomide) was a confirmed hit, and we 
showed that this compound completely prevented forma-
tion of craniofacial cartilage ( Fig. 4 A).
 Temporal and Functional Assessment of Selected 
Compounds 
 Representative images of the effects of 4 drug hits on 
craniofacial cartilage in wild-type embryos are shown in 
 Figure 4 . Treatment from mid-to-late epiboly (i.e., “time-
zero” in our drug screen) with cyclosporin A, climbazole, 
or escitalopram caused widening of the ceratohyoids and 
ceratobranchials and an overall reduction in the lower 
jaw cartilage, when observed ventrally at 5 dpf ( Fig. 4 A). 
In lateral view, the ceratohyoids and Meckel cartilage can 
be seen to be smaller than in control-treated embryos and 
downturned ( Fig. 4 A’). In all 3 cases, the ethmoid carti-
lage of the upper jaw is present and appeared normal. For 
each of these drugs, treatment from 29 hpf led to much 
less severe defects ( Fig. 4 B, B’). Quantitative increases in 
the angle between the ceratohyoids in embryos treated 
from this later time point were most apparent for cyclo-
sporin A. Treatment of embryos with leflunomide from 
E50 prevented the formation of any cartilage ( Fig. 4 A), as 
reported previously [White et al., 2011]. Remarkably, we 
found that all embryos treated from 29 hpf, after the crit-
ical window of NCSC specification and migration [Luo et 
al., 2001; Carney et al., 2006], were able to form both up-
per and lower jaw cartilage, although these structures 
were grossly abnormal ( Fig. 4 B). This phenotype has not 
been reported previously and suggests that leflunomide 
treatment has independent dual effects, inhibiting early 
NCSC induction and influencing later pharyngeal arch 
patterning and/or cartilage remodelling. We confirmed 
that early treatment with leflunomide completely inhib-
ited cranial NCSCs, as demonstrated by in situ  hybridisa-
tion for  sox10  (see below). Collectively, these results hint 
at the importance of the timing of drug treatments in re-


























 Fig. 4. Examples of drug re-testing on wild-
type zebrafish. Alcian blue-stained zebra-
fish at 5 days post-fertilisation showing jaw 
cartilage following drug treatment from 
embryonic day (E) 50 ( A ,  A’ ) or 29 hours 
post-fertilisation (hpf) ( B ,  B’ ).  A ,  B Ventral 
views.  B ,  B’ Lateral views of the same ani-
mals. 





 Leflunomide is an inhibitor of dihydroorotate dehy-
drogenase (DHODH), an enzyme that is essential for the 
production of uracil monophosphate, a constituent base 
that is integral to ribosomal RNA synthesis and ribosome 
biogenesis [Trainor and Merrill, 2014]. Cyclosporin A is 
an inhibitor of calcineurin, which is a calcium-depen-
dent serine/threonine protein phosphatase [Kaminuma, 
2008]. In response to increased intracellular calcium, cal-
cineurin dephosphorylates the nuclear factor of T-cells 
(NFAT) transcription factors, allowing their entry into 
the cell nucleus where they drive transcription.  Nfatc1 -
deficient mice exhibit osteopetrosis within the long bones 
owing to reduced numbers of bone-resorbing osteoclasts. 
Importantly in the context of craniosynostosis, they also 
have fewer osteoblasts and exhibit reduced formation of 
mineralised bone within the frontal bones of the skull 
resulting in wider cranial sutures [Winslow et al., 2006]. 
Given our initial hypothesis that compounds that inhib-
ited either NCSC identities or their differentiation could 
be candidates for treatment of craniosynostosis, we se-
lected leflunomide and cyclosporin A as representative 
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 Fig. 5. Temporal effects of leflunomide and 
cyclosporin A treatment at 5 days post-fer-
tilization. Left: Treatment regimens 1–10 
are schematised.  ↓ : Time point of drug ap-
plication. Red lines indicate window or 
drug treatment before either embryo col-
lection or drug washout.  ↑ : Arrows repre-
sent embryo collection. Right: Graphs 
show angles between ceratohyoid cartilag-
es for each experimental group. Error bars 
represent standard errors. E, embryonic 
day; hpf, hours post-fertilization. 





 We next undertook a full quantitative temporal analy-
sis of the effects of 10 μ M doses of these 2 drugs using 
wild-type embryos stained with Alcian blue. In treatment 
regimens 1–5, embryos were treated from progressively 
delayed 24-h time points and visualised at 5 dpf, while in 
treatment regimens 6–10, embryos were treated during 
24-h intervals using drug washout ( Fig. 5 ). The angle of 
the ceratohyoid cartilage was quantified for approximate-
ly 10 zebrafish for each regimen for control- and drug-
treated embryos. We noted some variability in this angle 
in control-treated animals in different clutches of fish, 
and so we have included this value for matched clutch-
mate controls for direct comparisons to be made. While 
leflunomide prevented cartilage formation when applied 
from E50 ( Fig.  4 ), treatments from either 24 or 48 hpf 
(regimens 2 and 3) were compatible with jaw cartilage 
formation but severely enhanced the angle of the cerato-
hyoid ( Fig. 5 ). By contrast, treatment after 48 hpf had no 
effect. Interestingly, treatment during day 1 or 2 only 
(regimens 6 and 7) was compatible with cartilage forma-
tion but caused patterning defects of similar magnitude 
to regimens 2 and 3. Treatment during day 3 caused only 
subtle patterning defects. Interestingly, we also found 
that treatment with leflunomide for 5 days did permit for-
mation of cartilage when the dose was diluted by 20-fold, 
showing that lower doses are consistent with at least par-
tial NCSC induction ( Fig. 6 ). We conclude that lefluno-
mide treatment inhibits cartilage formation during day 1 
and disrupts cartilage patterning/differentiation during 
day 2, but that in both cases, sustained treatment is re-
quired to exert these effects. For cyclosporin A, we found 
that sustained treatment between 2–5 dpf was sufficient 
to disrupt cartilage, identifying day 2 as the critical effec-
tive window, although transient 24-h treatments at any 
time point were not sufficient to disrupt the lower jaw 
( Fig. 5 ). For both drugs, these results identify day 2 as a 
critical window when the targets of these drugs regulate 
cartilage patterning/remodelling and suggest that com-
pensatory mechanisms can restore normal cartilage for-
mation if drug treatment is attenuated subsequently.
 Finally, to begin to investigate potential cellular and 
mechanistic targets of these drugs, we performed qRT-
PCR on 4-dpf zebrafish treated with 10 μ M teriflunomide 
or FK506 from 29 hpf to monitor markers of key skeletal 
cell types and cartilage matrix regulatory enzymes using 
procedues and primers previously reported [Pashay Ahi 
et al., 2016] ( Fig. 7 ). Teriflunomide treatment reduced ex-
pression of the osteoblast marker  spp1 and increased ex-
pression of  ctsk which is expressed in osteoclasts, sugges-
tive of reduced osteoblast and expanded osteoclast cells. 
Notably, expression of  rankl which promotes osteoclast 
formation through paracrine signalling was reduced, 
which could reflect a feedback mechanism. Terifluno-
mide also reduced expression of the chondrocyte marker, 
 col2a1 . Expression of cartilage matrix degrading metal-
loproteinase enzymes  mmp9  and  mmp13  was increased, 
while the inhibitor of these enzymes,  timp2a , was re-
duced. These findings are consistent with reduction in the 
jaw cartilage observed following leflunomide/terifluno-
mide treatment. The same general patterns were observed 
following FK506 treatment, although the effects were less 
pronounced. Collectively, these results suggest that drug 
treatments influence several key skeletogenic cell types 
and reduce cartilage extracellular matrix.
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 Fig. 6. Dose-response of leflunomide treat-
ment. Representative images in ventral 
view at 5 days post-fertilization showing 
effects of indicated doses of leflunomide 
treatment from 50% epiboly. 





 Functional Validation of Leflunomide through 
Inhibition of NCSC-Derived Neuroblastoma Cells 
 Perturbation drug screens rely on careful selection of 
a clinically relevant cell type(s), and because of their dis-
ruptive nature, they require subsequent testing in mam-
malian disease models. To ascertain whether our drug 
screen could have any relevance to NCSC-related diseas-
es, we began to assess the clinical potential of leflunomide 
and cyclosporin A in radically different biological settings 
to the zebrafish jaw.
 A first consideration is potential off-target effects of a 
drug. For this, we tested for phenocopy of the very spe-
cific cartilage-loss phenotype associated with lefluno-
mide treatment in zebrafish using a functional analogue. 
Treatment of embryos with a 10 μ M dose of terifluno-
mide, which is a metabolic derivative of leflunomide, 
identically reproduced the absence of cartilage formation 
in all embryos tested ( Fig. 8 A). Given that this phenotype 
is consistent with inhibition of NCSC induction, we as-
sessed  sox10  by in situ  hybridisation as a marker of en-
dogenous cranial NCSCs. Indeed, leflunomide treatment 
completely blocked formation of  sox10+  NCSC forma-
tion, although expression within the otic vesicles was pre-
served, where  sox10 is known to play independent roles 
in formation of the ear primordium ( Fig. 8 A). Collective-
ly, these results confirm that DHODH inhibition inhibits 
NCSC induction.
 We next chose to investigate the effects of lefluno-
mide/teriflunomide treatment on human NCSC-derived 
neuroblastoma cells, as inhibition of NCSC identities in 
these cells has shown to be of therapeutic value. Specifi-
cally, persistent  Sox10 expression has been shown to drive 
neuroblastoma formation, and depletion of  Sox10 can in-
hibit NCSC-derived tumour formation [Nagashimada et 
al., 2012; Shakhova et al., 2012; Kaufman et al., 2016]. We 
therefore hypothesised that chemical inhibition of 
DHODH may be therapeutically relevant in neuroblas-
toma. Treatment of several neuroblastoma cell lines with 
either leflunomide or teriflunomide caused a dose-de-
pendent reduction in viability ( Fig. 8 B). By contrast, SK-
N-AS cells, which are known to exhibit generalised drug 
resistance mechanisms [Cohen et al., 1995; Gatsinzi et al., 
2012], were more resistant to drug treatment, thereby 
serving as a control for non-specific toxic effects of the 
drug. Subsequent to this work, a separate study confirmed 
our findings, reporting that leflunomide treatment re-
presses neuroblastoma tumour growth in vivo, by  inhib-
iting proliferation, enhancing apoptosis, and inducing S-
phase arrest [Zhu et al., 2013]. Therefore, leflunomide is 
a potential new lead for development of therapeutics in 
neuroblastoma. Current chemical treatment options for 
neuroblastoma include application of retinoic acid which 
induces cellular differentiation and production of den-
drites, leading to cellular senescence. In contrast, we 
found that leflunomide treatment did not cause dendrite 
production, indicating that this drug works through a dis-
tinct mechanism ( Fig. 8 B).
 To gain mechanistic insight into the effects of DHODH 
inhibition in NCSCs, we used RNAseq to identify global 
gene expression changes following teriflunomide treat-
ment of SK-N-SH neuroblastoma cells ( Fig. 8 C) – full da-
taset given in online supplementary Table 1 (see www.
karger.com/doi/10.1159/000491567 for online suppl. 
material). In total, 133 genes exhibited at >2-fold change 
in expression levels (adjusted  p value <0.05) following 24 





























































 Fig. 7. Effect of drug treatments on skeletogenic gene expression markers. Zebrafish were treated with terifluno-
mide or FK506, as indicated from 29 hours post-fertilization to 4 days post-fertilization. Error bars are standard 
errors of the mean. Expression of indicated genes was assessed relative to wild-type (WT) zebrafish treated with 
DMSO, using primers and procedures as reported previously [Pashay Ahi et al., 2016]. 














































































Neuromuscular process controlling balance
Neuron projection morphogenesis
Translation
SRP-dependent cotranslational protein targeting to membrane
Nuclear-transcribed mRNA catabolic process, nonsense-mediated decay
 Fig. 8. Functional evaluation of DHODH inhibition.  A Phenocopy 
of cartilage-loss phenotype following treatment with 10 μ M teri-
flunomide between 50% epiboly to 5 days post-fertilization, 
and inhibition of  sox10 expression at 24 hours post-fertilization 
following teriflunomide treatment, shown by in situ hybridisation. 
 B Dose-dependent inhibition of cell numbers in SK-N-SH ( n = 6), 
LAN5 ( n = 3), and SK-N-AS ( n = 5) cells after 3 days treatment 
with leflunomide. Data are from CCK8 assays with untreated con-
trols given an arbitrary value of 1. All 100 μ M samples are signifi-
cantly different from untreated samples ( p < 0.05). Furthermore, 
at 100 μ M both SK-N-SH and LAN5 are significantly more sensi-
tive than SK-N-AS (LAN5:SK-N-AS,  p = 0.025; SK-N-SH:SK-N-
AS,  p = 0.002; ANOVA with post-hoc Scheffé test). Images show 
morphology of cells treated with 100 μ M leflunomide for 3 days 
(note no increase in neurite formation, a differentiation marker). 
 C Gene ontology terms statistically significantly enriched within 
the list of differentially expressed genes (log 2 -fold change >2,  p < 
0.05) according to DAVID software analysis. Number of terms 
within each category is listed.  * * * *  p < 5 × 10 –5 ;  * * *  p < 10 –4 ;  * *  p < 
10 –3 ;  *  p < 10 –2 ; no asterisk,  p < 0.05. 





for genes involved in transcription, RNA processing and 
translation. Consistent with known roles of DHODH in 
ribosomal RNA synthesis and ribosome biogenesis 
[Trainor and Merrill, 2014], of 67 downregulated genes 
with an adjusted  p value  <0.05, seven (10.4%) encoded 
ribosomal proteins (of 307 downregulated genes at the 
less significant  p  value  <0.05 cut-off, 15 (4.9%) encoded 
ribosomal proteins). In contrast, no ribosomal genes were 
upregulated, thereby suggesting that leflunomide/teriflu-
nomide inhibit neuroblastoma cell viability through 
blockade of ribosome biogenesis.
 Functional Validation of Tacrolimus as a Potential 
Therapeutic Compound in Craniosynostosis 
 FK506 (tacrolimus) is a more potent functional ana-
logue of cyclosporin A. We therefore chose to focus on 
this drug to evaluate the therapeutic relevance of target-
ing calcineurin signalling in craniosynostosis. Treatment 
of zebrafish with 10 μ M FK506 from E50 until 5 dpf caused 
identical jaw cartilage patterning defects that we demon-
strated using cyclopsorin A (data not shown), thereby ex-
cluding off-target effects as causes of this phenotype.
 Given the importance of osteoblasts in craniosynostosis 
pathogenesis, we began by testing the effect of tacrolimus 
treatment on primary osteoblasts. Culture of these cells for 
14 days led to expression of osteoblast progenitor, pre-os-
teoblast and mature osteoblast markers, including  Col1a1 , 
 ALP ,  Runx2 ,  and  Osx  ( Fig. 9 A), indicating that this proto-
col enriched for actively differentiating osteoblasts. These 
cells were treated with a 10-fold dilution series of FK506 
within the range 0–10 μ M , which are doses that have previ-
ously been shown to correlate with the effects of genetic 
mutations in  Nfat  genes and are thus likely to be physio-
logically relevant [Winslow et al., 2006]. Generally, at high-
er FK506 concentrations, expression of osteoblast differ-
entiation markers was increased compared to control, with 
the maximal effect generally being achieved at 0.1 μ M . We 
next tested FK506 for rescue of craniosynostosis in a cal-
varial explant system that we and others have developed 
using Crouzon mice [Eswarakumar et al., 2006]. Whereas 
the coronal sutures fused bilaterally over the 2 weeks of 
culture in all untreated mutant explants, which manifested 
as a loss of overlap of the frontal and parietal bones and an 
obliterated suture, none of the FK506-treated mutant ex-
plants showed overt signs of fusion after 2 weeks of culture 
( p <  0.0001; Fisher exact test) ( Fig. 9 B). Quantification of 
the area of overlap between the frontal and parietal bones 
for both the left and right coronal sutures demonstrated 
complete obliteration of this suture in Crouzon mutant 
calvaria treated with DMSO alone, while there was no dif-
ference between Crouzon mutant calvaria treated with 
FK506 and either treated or untreated wild-type calvaria 
( p = 0.530 and 0.690, respectively;  t test) ( Fig. 9 B). These 
data provide initial evidence for the therapeutic potential 
of FK506 in craniosynostosis and supports the need for 
further in vivo  testing.
 Discussion 
 In this study, we undertook a perturbation-based 
screen of FDA-approved compounds using  sox10:gfp 
 transgenic zebrafish. This transgene allowed direct visu-
alisation of NCSC-derived craniofacial cartilage that 
makes up the jaw, without the need for additional stain-
ing procedures. We noted partial toxicity of this trans-
gene which manifested as a quantitative increase in the 
angle between the ceratohyoid cartilages. Thus, it is likely 
that our screen was sensitised for defects in NCSC-de-
rived craniofacial cartilage. All 14 hits in our screen were 
reproducible in wild-type/non-transgenic zebrafish con-
firming that they are not artefacts. Our confirmed drug 
hit rate was 2.2% of the tested compounds. This is consis-
tent with previously reported perturbation screens [Pe-
terson et al., 2004; Stern et al., 2005; North et al., 2007; 
Kitambi et al., 2009; Ishizaki et al., 2010; Paik et al., 2010; 
Rihel et al., 2010; Ni et al., 2011; Peal et al., 2011; Rovira 
et al., 2011; Namdaran et al., 2012; Ridges et al., 2012; Gut 
et al., 2013; Le et al., 2013; Kong et al., 2014; Mork and 
Crump, 2015] suggesting that this screen design had good 
sensitivity. As discussed in the introduction, while pub-
lished perturbation screens have an average 29-fold in-
creased hit rate as compared to modifier screens, their 
success in potential clinical translation is likely to depend 
on selection of a specific cell type assessed in the screen as 
well as further testing in mammalian disease models. Re-
purposing screens using FDA-approved drugs have the 
advantage that drugs have already passed safety testing in 
humans. This is important because AstraZeneca reported 
that data linking a biological target to disease in human 
subjects and samples were available for 73–82% of the 
projects that remained active in Phase II, whereas 57–60% 
of the projects failed on the basis of efficacy where human 
data was not previously available [Cook et al., 2014].
 Our screen focused on NCSC derivatives within the 
craniofacial cartilage and could therefore identify com-
pounds that regulate NCSCs or remodelling of cartilage/
chondrocytes. Since osteoblasts and osteoclasts are also 
located throughout this cartilage around the time points 
that we analysed [Eames et al., 2013; Sharif et al., 2014; 
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Mork and Crump, 2015], it is conceivable that our screen 
could also identify compounds that influence these cell 
types, although we note that no mineralised bone is pres-
ent at these stages. Indeed, our temporal analyses of leflu-
nomide treatment suggested biphasic effects in repress-
ing early NCSC induction and later independent effects 
on cartilage remodelling. By contrast, our temporal anal-
yses of other drug hits, including cyclosporin A, support-
ed roles limited to cartilage remodelling. For both drugs, 
our data suggested that sustained drug treatments are also 
important to reproduce jaw patterning defects, which 
raises the possibility that compensatory mechanisms can 
restore normal formation of the jaw. In future, it will be 
interesting to characterise the exact cellular targets of 
these drugs as well as drug treatment timing and duration 
when considering possible clinical application (e.g., cra-
niosynostosis). For both drugs, we were also able to gen-
erate initial ex vivo data suggesting their potential rele-
vance for treatment of neuroblastoma or craniosynosto-
sis in mammalian systems. While these data provide some 
proof-of-concept support for our drug screen, it will be 
necessary to undertake further pre-clinical testing in pre-
cise in vivo models of disease treatment, and this will 
form the subject of future reports.
 Fig. 9. Functional assessment of calcineu-
rin inhibition in skeletogenesis.  A Relative 
expression of osteoblast differentiation 
marker genes normalised to untreated 
cells.  *  p < 0.05,  * *  p < 0.005 ( t test).  B E18.5 
calvarial explants cultured for 2 weeks in 
the presence or absence of 100 n M FK506. 
Top row:  Low-power view of a control ex-
plant; note overlap of the midline parietal 
bones (arrows), showing continued osteo-
genesis of the sutures (1st and 2nd images). 
Whereas the DMSO-treated C342Y/+ cor-
onal sutures undergo synostosis, FK506-
treated C342Y/+ explants do not (arrows, 
3rd and 4th images). The last image shows 
how the area of overlap of the frontal and 
parietal bones was measured over a fixed 
1-mm length of suture (outlined) to gain a 
robust measure of suture width. These val-
ues are summarised over 33 explants, either 
wild-type (WT) or mutant (Mut), treated 
with DMSO or FK506. Values are given for 
both the left and right sutures for each ex-
plant. 





 Of our drug hits, 50–64% are known to target path-
ways implicated in osteoarthritis (OA) pathogenesis or 
regulation of bone mineral density ( Table 1 ) [Mazziotti 
et al., 2010], and at least 1 drug disrupted early NCSC 
development. This likely reflects the design of our screen 
which visualised patterning of NCSC-derived skeletal el-
ements. Thus, the hits that we report could be relevant to 
skeletal tissue homeostasis and disease in a number of 
different contexts and emphasise the transferability of 
the perturbation screen design when focused on a spe-
cific cell/tissue type of medical relevance. Chondrocytes 
represent a key cellular component of articular cartilage 
which is affected in all joints with OA [Buckwalter et al., 
2005]. Changes within the microenvironment of the 
joint can induce an inflammatory response, whereby 
chondrocytes release cytokines (e.g., IL1β) and matrix-
degrading enzymes. Joint destabilisation can lead to in-
creased expression of metalloproteinases, such as AD-
Table 1.  List of drug hits, description and evidence supporting links to osteoarthritis pathogenesis and bone mineral density reduction 
in humans
Drug Target Biochemical/cellular targets Evidence that this compound 
reduces bone mineral density 
in humansa
Evidence for relevance to OA
Novel hits
Vinorelbine Anti-mitotic/chemotherapy Mitosis, tubulin No –
Cyclosporin A Calcineurin inhibitor pCaN; pNFAT; couples to AP-1 
transcription factor involving cJun
Yes Calcineurin participates in the progression 
of OA, and mice lacking the downstream 
transcription factor, Nfatc2, exhibit joint 
degradation and abnormal chondrocyte 
anabolism/catabolism [Yoo et al., 2007; 
Wang et al., 2009; Beier, 2014]
Nicardipine HCl L-type Ca2+ channel blocker No L-type Ca2+ channel blocker, verapamil, 
protects against OA [Takamatsu et al., 
2014]
Climbazole Anti-fungal No –
Clomiphene Selective oestrogen receptor 
modulator
Oestrogen receptors translocate to 
the nucleus acting as transcription 
factors
Yes Oestrogen receptor polymorphisms are 
associated with OA risk and oestrogen may 
account for higher OA incidence in women 
[Bay-Jensen et al., 2013; Yin et al., 2015]
Adapalene Retinoid Possible control of transcription 
through retinoic acid receptors
Yes RA ligands are elevated in OA and induce 
ADAM28 expression and proteoglycan 
degradation in chondrocytes [Davies et al., 
2009; Hikichi et al., 2009]




No Increased expression of dopamine 
receptors in synovial fibroblasts in 
rheumatoid arthritis [Capellino et al., 
2014]
Amoxapine Serotonin/epinephrine re-uptake 
inhibitor
Increases ligand upstream of PKC Yes –
Escitalopram Selective serotonin re-uptake inhibitor Increases ligand upstream of PKC Yes –
Nisoldipine Calcium channel blocker Upstream of CaN and NFAT Yes L-type Ca2+ channel blocker, verapamil, 
protects against OA [Takamatsu et al., 
2014]
Known hits
Leflunomide DHODH inhibitor DHODH No –
Retinoic acid Retinoic acid signalling Possible control of transcription 
through retinoic acid receptors
Yes RA ligands are elevated in OA and induce 
ADAM28 expression and proteoglycan 
degradation in chondrocytes [Davies et al., 
2009; Hikichi et al., 2009]
Diazoxide Potassium channel activator Electrochemical signalling No Potassium channels are expressed in 
articular chondrocytes [Mobasheri et al., 
2007]
Pimozide Anti-psychotic No –
Functional analogues
Tacrolimus (FK506) Calcineurin inhibitor pCaN; pNFAT; couples to AP-1 
transcription factor involving cJun
Yes Calcineurin participates in the progression 
of OA, and mice lacking the downstream 
transcription factor, Nfatc2, exhibit joint 
degradation and abnormal chondrocyte 
anabolism/catabolism [Yoo et al., 2007; 
Wang et al., 2009; Beier, 2014]
Teriflunomide Metabolic derivative of leflunomide DHODH No –
 DHODH, dehydroorotate dehydrogenase; OA, osteoarthritis. a Capellino et al., 2014.





AMTS5 and MMP13, which are downregulated follow-
ing joint immobilisation [Burleigh et al., 2012]. Several 
known human OA susceptibility genes, including  gdf5 
 and  mcf2l , are expressed in zebra fish craniofacial carti-
lage elements and joints from just a few dpf [Mitchell et 
al., 2013]. Analysis of zebrafish cartilage is therefore di-
rectly relevant to OA of the temporomandibular joint 
which affects approximately 17% of the OA patients 
[Gremillion et al., 1993].
 The drug hits fall into several functional categories, in-
cluding calcium, retinoic acid receptor, oestrogen, and 
neuropeptide signalling pathways ( Table 1 ). Leflunomide 
was the only compound for which we demonstrate clear 
evidence for direct effects on NCSCs, and this drug has 
previously been shown to inhibit  BRAF V600E -driven mel-
anoma cell growth, which has been proposed to reflect 
suppression of NCSC identities [White et al., 2011]. Our 
RNAseq data in neuroblastoma cells suggested that 
DHODH inhibition particularly affected ribosomal gene 
expression and transcription. NCSC-derived neuroblas-
toma cells are known to activate expression of ribosomal 
genes such that protein synthesis can keep pace with the 
demands of increased proliferation. This is driven by the 
protooncogene,  MYCN [Boon et al., 2001],  which is com-
monly activated in neuroblastoma.
 Cyclosporin A and FK506 are inhibitors of calcineu-
rin, which is a calcium-dependent serine/threonine pro-
tein phosphatase [Kaminuma, 2008]. In response to in-
creased intracellular calcium, calcineurin dephosphory-
lates the NFAT transcription factors, allowing their entry 
into the cell nucleus where they drive transcription. 
 Nfatc1 -deficient mice exhibit osteopetrosis within the 
long bones owing to reduced numbers of bone-resorbing 
osteoclasts. They also have fewer osteoblasts and exhibit 
reduced formation of mineralized bone within the frontal 
bones of the skull resulting in wider cranial sutures [Win-
slow et al., 2006]. Similar effects on osteoblast and osteo-
clast cell lineages have been observed in calcineurin β1 
mutant mice. Calcineurin β1 [Cnb1, also known as 
Ppp3r1, protein phosphatase 3, regulatory subunit B, al-
pha isoform (calcineurin B, type I)] is a Ca 2+ -binding reg-
ulatory subunit of heterodimeric calcineurin. Loss of the 
Cnb1 subunit results in a lack of calcineurin enzymatic 
activity in non-germline cell types. Conditionally target-
ed mutant mice whereby the  Cnb1 gene was inactivated 
in osteoblasts increased bone mineral density, associated 
with increased differentiation and mineralisation of pri-
mary calvarial osteoblast cultures, and failure of these os-
teoblasts to support osteoclast growth and survival [Win-
slow et al., 2006]. 
 These observations led us to hypothesise that FK506 
treatment could prevent cranial suture fusion in Crou-
zon syndrome mice, and we generated initial support for 
this idea using a calvarial explant system. To take this 
observation further in future, it will be necessary to test 
the drug in vivo, evaluate systems for localised drug de-
livery to avoid unwanted side effects, and to characterise 
the key skeletal cell type(s) that are influenced within the 
calvarium since calcineurin signalling can influence os-
teoblast and osteoclast cells and precursors. Of note, this 
compound is approved for long-term immunosuppres-
sion of very young babies who undergo organ transplan-
tation, suggesting that it may also be efficacious for 
treatment of craniosynostosis over the first few years of 
life.
 In summary, the identification of new chemical struc-
tures that influence NCSC-derived skeletal structures 
provides new insight into global mechanisms of skeleto-
genesis and provides a basis to begin to explore possible 
treatments for conditions such as craniosynostosis. We 
add to the growing literature concerning use of zebrafish 
as an in vivo system for chemical screening, which is an 
important application of this model organism. In future, 
it will be necessary to characterise these and other drug 
hits that regulate craniofacial development, including the 
particular target cell lineages and the utility of these com-
pounds in mammalian disease models.
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